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ABSTRACT 
Background: Routine HIV testing in healthcare settings is recommended by UK 
guidelines when the local diagnosed HIV prevalence >0·2%. This prospective study 
assessed the costs and cost-effectiveness of routinely offering HIV tests in four 
settings: Emergency Department, Acute Care Unit, Dermatology Outpatients and 
Primary Care.  
 
Methods: As part of the HINTS study, HIV tests were offered to patients aged 16-65 
over three months in 4 settings: Emergency Department, Acute Care Unit, 
Dermatology Outpatients and Primary Care Centre in London. We assessed the costs 
of screening in terms of costs per newly diagnosed HIV-infected patient using the data 
derived from the study. Additionally, national data from the Health Protection 
Agency’s Survey of Prevalent HIV Infections Diagnosed (SOPHID) was used to 
estimate the number of undiagnosed individuals attending each setting over a one year 
period. A sensitivity analysis was run to simulate the costs and cost-effectiveness of 
HIV screening in different scenarios: applying the modelled undiagnosed HIV 
prevalence, and changing the HIV test offer and test uptake rates.  
 
Results: Testing as per the HINTS Study cost £19,056 per newly diagnosed patient. 
Assuming all undiagnosed persons had been offered a test and applying the same test 
uptake rate as the study (67%), the cost per newly diagnosed patient becomes £4,460. 
In the best possible scenario, assuming 100% coverage and 100% test uptake, the cost 
per new diagnosis in the HINTS settings amounts to £2,940.  
 
Discussion: The results of this study are encouraging and suggest that a screening 
programme in a high prevalence area could identify HIV-infected patients at a low 
cost per diagnosis. Earlier diagnosis of HIV infection may have further cost benefits 
in terms of early treatment and aversion of incident infections. 
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1.  Introduction 
In 2009, 26% of all adults living with HIV infection in the UK were estimated to be 
undiagnosed.
1
 More than half of  those newly diagnosed presented at a late stage, with 
a CD4 count of less than 350 per μl.1 Late diagnosis of HIV infection is associated 
with poorer responses to antiretroviral therapy
2,3
 and a worse prognosis.
4
 A significant 
number of HIV-infected patients will present to health care providers with symptoms 
attributable to HIV infection in the period preceding their diagnosis, without the 
underlying diagnosis being made.
5
 
Beyond the value to the individual, efforts to reduce the undiagnosed fraction may 
have public health benefits not only in epidemiological but also in economic terms.  
Late diagnosis and consequent late treatments decrease life expectancy and are more 
expensive if compared to early ones.  
An estimated 50% of new HIV infections in the US are transmitted by the 25% of 
HIV-positive individuals unaware of their status.
6 
Knowledge of HIV status reduces 
risk behaviours
7
 and effective antiretroviral therapy reduces transmission risk: thus 
earlier diagnosis is likely to reduce HIV transmission at a population level.
8
 Reduction 
in transmission rates has certainly a huge impact in terms of avoided costs to treat 
newly diagnosed patients.   
 
Routine HIV testing in antenatal care and sexual health clinics in the UK has greatly 
increased HIV testing rates.
1,13
 Routine testing has been shown in an RCT to be 
acceptable to patients and to cause no undue anxiety.
14
 
The HIV Testing in Non-traditional Settings (HINTS) study investigated the 
feasibility and acceptability, to patients and staff, of delivering routine HIV testing in 
non-specialist settings in areas of high HIV prevalence (reference). In this study we 
assess the costs and cost-effectiveness of the HIV testing programme.   
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2.  Methods 
2.1  Clinical Sites, Study Participants and Methods: 
The HINTS study was a multi-site, observational study conducted across four sites in 
London, UK: an Emergency Department (ED), an Acute Care (medical and surgical 
admissions) Unit (ACU), a Dermatology Outpatient Clinic (OPD), and a Primary Care 
Centre (PC). All are located within areas of diagnosed HIV prevalence >2/1000. 
 
During the study phase, HIV testing was delivered to patients. Inclusion criteria 
comprised all adults aged between 16 and 65 years: (i) not known to be HIV positive, 
(ii) accessing the healthcare setting for the first time over the testing period, and (iii) 
able to consent to a test. 
The model of testing varied according to clinical sites (Table 1). Oral fluid-based HIV 
testing was used in the PC, ED and OPD arms, and was performed using a fourth-
generation assay on a modified platform to detect HIV-1 antibodies (Duo test). In the 
ACU, fourth-generation HIV serology was performed on serum samples obtained 
during the inpatient admission. 
The fourth generation tests provide accurate results after just 28 days after possible 
exposure to HIV.   
 
Patients with a reactive HIV test were recalled to undergo confirmatory INSTI HIV 
test. An additional Abbot Determine test was performed to screen positives. A 
helpline number was provided, and sexual health counsellors were available to all 
patients upon request.  
 
2.2 Data Capture: 
  
Electronic patient records were used to capture age, sex, ethnicity, reasons for non-
offer of HIV test (including ineligibility) and the outcome of the test offer. All data 
were anonymised prior to analysis. Data were held in line with the Data Protection 
Act 1998 and local Trust policies. 
 
2.3 Primary outcomes: 
The primary outcome measures of this quantitative arm of the study comprised: 
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 The number of patients undertaking the test, the results, the confirmatory tests 
(for each setting)  
 The costs for testing, costs for confirmatory testing on false reactive 
 The costs for testing positives 
 The staff costs 
 The promotional materials  
 The total costs of the screening programme 
 The effectiveness of the programme (in terms of new diagnosis)  
 
2.4 The analysis 
A cost analysis was done to calculate the cost of the HINTS screening programme in 
the four scenarios. The costs include the screening kit, the laboratory, the staff and the 
cost to run and promote the programme.  
A cost-effectiveness analysis has been carried out using the cost data and the 
effectiveness outcomes (number of true positives new diagnosed) collected in the 
HINTS study for each setting.  
The total costs of the screening programme (including the costs for tests, laboratory, 
staff and promotional costs) have been compared to the number of new diagnosed 
patients to obtain a cost-effectiveness ratio.  
The Survey of Prevalence HIV Infection Diagnosed (SOPHID) was used to estimate 
the prevalence for the demographics in each setting and to estimate the number of 
undiagnosed individuals who potentially could attend in one year. A simulation of the 
cost-effectiveness results has been done using the data from the Survey to understand 
how the results change assuming the programme could potentially reach a higher rate 
of undiagnosed patients.  
The analysis has been done assuming three different scenarios:  
- the base case - HINTS study: using the data coming from the real study carried 
out in 4 settings  
- the SOPHID scenario: using the SOPHID data we estimated the undiagnosed 
prevalence in each setting and run the analysis again with the new numbers 
assuming the same compliance rate as in the real study ; 
6 
 
- the SOPHID best scenario: using the SOPHID data we estimated the 
undiagnosed prevalence and the numbers of undiagnosed patients in each 
setting and we run the analysis assuming a 100% compliance.  
 
 
3.  Results 
3.1 HIV Testing Data: 
Across all four sites, there were almost 15 000 potential age eligible attendees, of 
those 13 855 were age eligible attendees for the study and offered the test. 7033 
(51%) were approached by study personnel (Table 2). Of this number, 839 (11·6%) 
were subsequently considered ineligible to test.  Of the 6194 patients offered an HIV 
test, 4105 accepted this offer, with a 66·8% compliance. The number of reactive tests 
was 15, of those 7 were false reactive. Eight individuals were newly diagnosed with 
HIV infection, and all were successfully transferred to care (two partners were 
subsequently diagnosed with HIV infection via partner notification). HIV 
seropositivity across the sites was 1.9/1000 (95% CI 0·6 – 3·2/1000). 
 
3.2 Cost Data: 
Test costs 
The costs for screening differ across the four sites, according to the testing method. It 
includes the kit and the laboratory. In the ED the oral fluid sample costs £5.60, in the 
AC the whole serum costs £2.50, whereas in the PC and OPD it is more expensive, 
costing £6.98 and £ 10.30 respectively (table 3).  
The cost for carrying out confirmatory testing on false reactive is estimated, based on 
local cost for serology and it also includes the cost to repeat the screening and £6 for 
the Insti test.  
The cost for screening positives is estimated based on local cost for serology and it 
includes the £6 for Insti and the £7.36 for the Abbot Determine.   
According to the unitary costs and the screening results, the total costs for screening 
negatives were £25,906.86, the total costs of screening false reactive patients were 
£143.06 and £181.52 for true positive patients.  
 
Staff cost 
We assessed the costs for the staff involved in each site for the screening programme.   
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Two researchers have been employed for 12 months for 0.5 WTE, at a B7 equivalent 
salary spine to work across the all settings.  
In the Emergency Department (ED) a testing team was employed for 3.5 months at 
1.00 WTE to work 98% of the time, a research nurse was employed for 3 months for 
1.0 WTE at a B6 equivalent salary spine). In the Acute Setting a research nurse was 
employed for 3 months for 1.0 WTE at a B6 equivalent salary spine.  In the OPD a 
research nurse was employed for 3 months for 1.0 WTE at a B7 equivalent salary 
spine. In the Primary Care setting a testing team was employed for 3.5 months at 1.00 
WTE to work 2% of the time, one GP was employed for 5 months, for 0.2 WTE. In 
the Primary Care setting an additional incentive of £10.00 for test carried out was 
offered to the GP.   
The total staff costs for the entire programme was £ 124,219, including £ 64,199 for 
staff, £ 50,000 for the study coordinators and £ 10,020 for the GP incentive (table 3) 
 
Other costs 
Promotional materials, including leaflets, patient’s info sheets and posters have been 
estimated £2,000, equally spread across each site (table 3). 
 
Total cost 
In conclusion, the total cost for the screening programme across the four sites was 
respectively £56,339.56 in ED, £31,659.40 in OPD, £ 25,034 in AC and £39,386.06 in 
PC, for a total cost of £152,439.02 for the entire programme (table 3). 
 
3.3 Cost-effectiveness results in the base case HINTS scenario 
The testing programme detected new 8 undiagnosed infected patients over 7033 
participants in four months. 
The total cost of the programme was £152,439.02. If we compare the costs with the 
effectiveness data, the testing costs £19,054.88 for a newly diagnosed HIV infected 
(table 3).  
If on one hand it is quite expensive to diagnose a new HIV case, the cost is on line 
with the threshold suggested by NICE and do not take into account the costs saved 
due to avoided transmission.  
 
4. Sensitivity analysis.  
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4.1 The simulation using SOPHID data 
The Survey of Prevalence HIV Infections Diagnosed (SOPHID) was used to estimate 
the prevalence for the demographics across each setting and to estimate the number of 
undiagnosed individuals who will attend (per year and per quarter). According to the 
prevalence modelled for the demographics of each setting, we estimated that 77,700 
undiagnosed individuals would attend the 4 settings in one year. The estimated 
undiagnosed prevalence would be 0.47% (table 4). 
Assuming that the staff would be able to approach the same rate of patients as in the 
HINTS scenario   almost 48,000 patients will be asked to have a test. Assuming in 
each setting we will have the same compliance rate than in the HINTS, almost 26,000 
patients will have a diagnostic test. According to the specificity and sensitivity of the 
test almost 120 patients will be diagnosed HIV positive. The false positives will be 
around 44.  
The total cost for screening tests will be £ 155,993 (table 4). 
We assumed that the staff employed for the HINTS scenario could work in the 4 
settings according to the new numbers and for an entire year (instead of 3 months).  
Except for the study coordinators, who were already working for 12 months, the cost 
of the staff was recalculated assuming a work load of 12 months.  
The total cost for staff in this new scenario increased to £ 373,220 (including 301,985 
for staff, £ 50,000 for coordinators and £ 21,235 for GP incentives, according to the 
new tests intake). 
The total cost for the screening programme will be £ 531,214 and compare to the 
newly diagnosed patients, the cost effectiveness will decrease to £ 4,460 for patient 
(table 4). 
 
4.2  The best case scenario using the SOPHID  
The analysis was run assuming the best scenario ever, where all the undiagnosed 
patients could be reached and tested. Assuming the staff could reach all the patients 
who attended the 4 settings and assuming a compliance rate of 100%, all the 
undiagnosed patients were found positive. 
We also assumed that the specificity and sensitivity of the test remain the same.  
In this scenario all the 77,700 patients attending the settings accept to have a test. Of 
those, 367 are found positive and 132 false positive (table 5).  
According to these outcomes the costs of the screening tests are £ 472,892 (table 5). 
9 
 
Again we assume that the staff will be employed as in the previous scenario, for 12 
months, but this time the work load will reflect the higher coverage, so the cost will 
increase of the same proportion needed to reach the 100% coverage. So for example, 
if in the ED the cost for the staff to cover 73.45% of the patients was £183,776, in the 
best scenario it was increased of 26.55%, increasing up to £ 232,564.   
The total cost for the screening program in the best scenario will be around £ 
1,077,635, with 367 new HIV diagnosed patients, so the cost effectiveness will 
improve to £2,940.34 for one new patient diagnosed (Table 5).   
 
5.  Discussion 
A previous study has assessed that HIV testing in these settings is acceptable to the 
majority of patients and staff, and is operationally feasible. According to this study the 
costs for testing in the four settings are quite high if we compare them to the number 
of newly diagnosed patients with HIV. The cost to diagnose a patient is almost £ 
19,120. However if we take into account the costs for testing in a period of one year 
according to the SOPHID data, the cost to detect a new HIV positive decrease to  
£4.460. These results are really encouraging and suggest that a screening programme 
in a high prevalence area could potentially diagnose new patients at a very low cost, 
with a great impact in terms of early treatments, reduction of transmissions and 
avoided future costs. If HIV testing is to be included as a routine part of patients’ care, 
additional staff training and infrastructural resources will be required, so these costs 
should be taken into account too.  
 
______________________________________________________ 
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Table 1: HINTS Study Sites  
Table 2: Coverage, uptake and seropositivity of routine offer of HIV test across the four sites 
  ED ACU PC OPD 
Age eligible attendees (n=15 042) 5541 1388 6337 1776 
Total study eligible attendees (first offer of test; 
not known HIV-positive) (%) (n=13 855) 
[95% CI] 
 
5505 (99·3%) 
 
[99·1%-99·6%] 
1298 (93·5%) 
 
[92·2%-94·8%] 
5352 (84·5%) 
 
[83·6%-85·4%] 
1700 (95·9%) 
 
[94·8%-96·7%] 
Coverage = eligible attendees approached (%) 
(n=7033) 
[95% CI] 
 
4070 (73·9%) 
 
[72·7%-75·1%] 
623 (48·0%) 
 
[45·3%-50·8%] 
1442 (26·9%) 
 
[25·8%-28·1%] 
898 (52·8%) 
 
[50·5%-55·2%] 
Clinically ineligible (% of all approached) 
(n=839) 
[95% CI] 
 
637 (15·7%) 
 
[14·5%-16·8%] 
75 (12·0%) 
 
[9·5%-14·6%] 
113 (7·8%) 
 
[6·5%-9·2%] 
14 (1·5%) 
 
[0·8%-2·4%] 
Total tests offered 
(n=6194) 
3433 548 1329 884 
Uptake = total tests accepted (%)  
(n=4105) 
[95% CI] 
 
2121 (61·8%) 
 
[60·2%-63·4%] 
384 (70·1%) 
 
[66·2%-74·0%] 
1002 (75·4%) 
 
[73·1%-77·7%] 
598 (67·6%) 
 
[64·6%-70·7%] 
Reactive HIV tests 
(n=15) 
6 4 5 0 
False reactive HIV tests 
(n=7) 
2 0 5 0 
Study Site  
(Trust and clinical setting) 
Primary Care 
Trust 
Diagnosed HIV  
Prevalence per 1000 
individuals 15-59 years  
(ranking in UK) 1 
Model of routine HIV testing service delivery 
Composition of HIV testing team (TT) 
Delivery model (DM) 
 
Testing phase 
(weeks) 
HIV testing method 
Sample (S) 
Assay (A) 
Platform (P) 
Confirmation (C) 
 
Chelsea and Westminster 
Hospital 
Emergency Department (ED) 
45 000 attendances/annum 
Kensington and 
Chelsea 
8·33 (4th) TT: seconded staff from ED, Sexual Health, non-clinical testers 
DM: two testers per testing shift on a rolling rota; planned coverage 
of all time periods and days 
 
15 S: Oral fluid (whole saliva sample) 
A: Bio-Rad Genscreen Ultra HIV Ag-Ab EIA test 
P: Biokit Best 2000  
C: Abbott Determine HIV 1/2 test 
Homerton University Hospital 
Acute Care Unit -  
Medical and Surgical 
Admissions Unit (ACU) 
4200 attendances/annum 
City and 
Hackney 
8·25 (5th) TT: seconded staff from mixed backgrounds (ED, Sexual Health, non-
clinical testers, research nurse) 
DM: single tester reviewed electronic bed state once daily and 
approached all age-eligible patients admitted in the preceding 24 
hours, still present in the ACU 
12 S: Whole serum 
A: Abbott Architect HIV Ag/Ab 4th generation assay 
P: Abbott Architect ci8200 Integrated System 
C: Confirmation on repeat 
Kings College Hospital 
Dermatology Outpatient 
Department (OPD) 
5000 attendances/annum  
Lambeth 13·28 (1st) TT: seconded staff from mixed backgrounds (dermatologists, Sexual 
Health, non-clinical testers, medical students) 
DM: Two testers present in each Clinic.  Patients offered HIV test 
prior to Dermatology consultation 
 
12 S: Oral fluid (sample collection with Oracol+ device, 
Malvern Medicals PLC, UK) 
A: Bio-Rad Genscreen Ultra HIV Ag-Ab EIA test 
P: TECAN RMP200  
C: Confirmation on repeat 
North End Medical Centre 
Primary Care (PC) 
13 671 registered patients 
aged 16-65 yrs (2010) 
Primary  
Hammersmith 
and Fulham 
8·15 (6th) TT: all GPs and nurses in the practice who had received focussed 
training  
DM: testing introduced to routine consultations in a staggered 
fashion 
 
14 S: Oral fluid (sample collection with Oracol+ device, 
Malvern Medicals PLC, UK) 
A: Bio-Rad Genscreen Ultra HIV Ag-Ab EIA test 
P: Biokit Best 2000  
C: Abbott Determine HIV 1/2 test 
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Newly diagnosed individuals;  
HIV seropositivity (per 1000) (n=8) 
[95% CI]  
 
4  
 
1·9 [0·05 – 3·8] 
4  
 
10·1 [0·3 – 20·5] 
0 0 
Proportion transferred to care 100% 100% n/a n/a 
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Table 3: Coverage, uptake, seropositivity and costs of routine offer of HIV test across the four sites 
HINTS SCENARIO ED OPD AC PC TOTAL  
      
A. Total number of attendances in 
the study period 
5541 1776 1388 6337 15042 
B. Total number of interactions 4070 898 623 1442 7033 
C. Coverage/interactions over 
potential eligibles [B/A] (%) 
73.45% 50.56% 44.88% 22.76% 46.76% 
D. Number of compliant patients 
who accepted the test 
2121 598 384 1002 4105 
E. Compliance [D/B] (%) 52.11% 66.59% 61.64% 69.49% 58% 
F. Number of confirmatory tests 
carried out 
6 0 4 5 15 
G. Number of true positives 4 0 4 0 8 
H. Number of false positives 2 0 0 5 7 
I. Number of negatives [D-G] 2117 598 380 1002 4097 
 J. Number of true negatives 
[I*SPECIFICITY] 
2113.4 4784.0 0.0 0.0 6897.4 
K. Unitary cost for screening 
negatives 
 £                     5.60   £                  10.30   £                     2.50   £                     6.98   
L. Unitary cost for carrying out 
confirmatory testing on false 
reactives
1
 
 £                  17.02   £                  24.00   £                  21.00   £                  18.40   
M. Unitary cost for screening 
positives
2
 
 £                  24.38   £                  30.92   £                  21.00   £                  25.76   
N. Total cost for screening negatives 
[K*I] 
 £          11,844.00   £             6,159.40   £                950.00   £             6,959.06   £          25,912.46  
O. Total cost for screening false 
reactives [L*H] 
 £                  34.04   £                         -     £                         -     £                  92.00   £                126.04  
P. Total cost for screening true 
positives [M*G] 
 £                  97.52   £                         -     £                  84.00   £                         -     £                181.52  
Q. Staff costs (see sheet 3)  £          31,384.00   £          12,500.00   £          11,000.00   £             9,315.00   £          64,199.00  
R. Study coordinators (x2 0.5 WTE)  £          12,500.00   £          12,500.00   £          12,500.00   £          12,500.00   £          50,000.00  
S. Incentives to GPs for testing [£10 
for test] 
    £          10,020.00   £          10,020.00  
T. Promotional material (patient 
info sheets and posters) 
 £                500.00   £                500.00   £                500.00   £                500.00   £            2,000.00  
U. TOTAL COST OF HIV SCREENING 
PROGRAMME HINTS 
[N+O+Q+R+S+T] 
 £          56,359.56   £          31,659.40   £          25,034.00   £          39,386.06   £        152,439.02  
      
V.Cost for a newly diagnosed HIV 
patient in HINTS [U/G] 
 £          14,089.89    £             6,258.50    £          19,054.88  
      
1
 estimated based on local cost for serology and £6 for Insti 
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Table 4: Coverage, uptake, seropositivity and costs of routine offer of HIV test across the four sites in the SOPHID 
scenario 
"SOPHID" SCENARIO EMERGENCY DEPT OPD ACUTE CARE PRIMARY CARE TOTAL  
Diagnosed prevalence modelled for the 
demographics of each setting (SOPHID) 
290 292 42 109 733 
Estimated undiagnosed individuals who will 
attend per year ( from SOPHID) 
145 146 21 55 367 
Total number of attendances in one year 55171 4864 4235 13430 77700 
Estimated undiagnosed prevalence (SOPHID) 
(%) 
0.26% 3.00% 0.50% 0.41% 0.47% 
Estimated number of undiagnosed that will 
have a test per year (SOPHID) 
56 49 6 9 119 
A. Total number of attendances in the study 
period 
55171 4864 4235 13430 77700 
B. Total number of interactions [A*C] 40524.45 2459.39 1900.87 3056.03 47941 
C. Coverage/interactions over potential 
eligibles (%)³ 
73.45% 50.56% 44.88% 22.76% 61.7% 
D. Number of compliant patients who accepted 
the test [B*E] 
21118.51 1637.77 1171.64 2123.54 26051 
E. Compliance (%)⁴ 52.11% 66.59% 61.64% 69.49% 58.37% 
F. Number of confirmatory tests carried out 
[G+H] 
91 52 8 12 163.31 
G. Number of true positives⁵   56 49 6 9 119.09 
H. Number of false positives  [I-J] 36 3 2 4 44.22 
I. Number of negatives [D-G] 21063 1589 1166 2115 25932.37 
 J. Number of true negatives [I*SPECIFICITY] 21027 1586 1164 2111 25888.15 
K. Unitary cost for screening negatives  £                     5.60   £                  10.30   £                     2.50   £                     6.98   
L. Unitary cost for carrying out confirmatory 
testing on false reactives1 
 £                  17.02   £                  24.00   £                  21.00   £                  18.40   
M. Unitary cost for screening positives2  £                  24.38   £                  30.92   £                  21.00   £                  25.76   
N. Total cost for screening negatives [K*I]  £        117,952.86   £          16,362.64   £             2,914.58   £          14,762.14   £        151,992.23  
O. Total cost for screening false reactives [L*H]  £                611.31   £                  65.01   £                  41.75   £                  66.36   £                784.44  
P. Total cost for screening true positives [M*G]  £             1,353.18   £             1,520.02   £                122.01   £                221.99   £            3,217.19  
Q. Staff costs (see sheet 3)  £        183,776.00   £          50,000.00   £          44,000.00   £          24,209.57   £        301,985.57  
R. Study coordinators (x1 1 WTE)  £          12,500.00   £          12,500.00   £          12,500.00   £          12,500.00   £          50,000.00  
S. Incentives to GPs for testing [£10 for test]     £          21,235.38   £          21,235.38  
T. Promotional material (patient info sheets 
and posters) 
 £                500.00   £                500.00   £                500.00   £                500.00   £            2,000.00  
U. TOTAL COST OF HIV SCREENING 
PROGRAMME SOPHID [N+O+Q+R+S+T] 
 £        316,693.35   £          80,947.68   £          60,078.34   £          73,495.44   £        531,214.81  
V.Cost for a newly diagnosed HIV patient in 
SOPHIS [U/G] 
 £             5,705.82   £             1,646.62   £          10,340.86   £             8,528.64   £            4,460.59  
1 estimated based on local cost for serology and £6 for Insti 
      
 
Table 5: Coverage, uptake, seropositivity and costs of routine offer of HIV test across the four sites in the SOPHID best 
scenario 
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"THE BEST" SCENARIO ED OPD ACUTE CARE PRIMARY CARE TOTAL  
Diagnosed prevalence modelled for the 
demographics of each setting (SOPHID) 
290 292 42 109 733 
Estimated undiagnosed individuals who will 
attend per year ( from SOPHID) 
145 146 21 55 367 
Total number of attendances in one year 55171 4864 4235 13430 77700 
Estimated undiagnosed prevalence (SOPHID) (%) 0.262819235 3.001644737 0.495867769 0.405807893 0.471685972 
Estimated number of undiagnosed that will have 
a test per year (SOPHID) 
56 49 6 9 119 
      
A. Total number of attendances in the study 
period 
55171 4864 4235 13430 77700 
B. Total number of interactions [A*C] 55171 4864 4235 13430 77700 
C. Coverage/interactions over potential eligibles 
(%)³ 
100% 100% 100% 100% 100% 
D. Number of compliant patients who accepted 
the test [B*E] 
55171 4864 4235 13430 77700 
E. Compliance (%)⁴ 100% 100% 100% 100% 100% 
F. Number of confirmatory tests carried out 
[G+H] 
239 154 28 77 498 
G. Number of true positives⁵   145 146 21 55 367 
H. Number of false positives  [I-J] 94 8 7 23 132 
I. Number of negatives [D-G] 55026 4718 4214 13376 77334 
 J. Number of true negatives [I*SPECIFICITY] 54932 4710 4207 13353 77202 
K. Unitary cost for screening negatives  £                     5.60   £                  10.30   £                     2.50   £                     6.98   
L. Unitary cost for carrying out confirmatory 
testing on false reactives1 
 £                  17.02   £                  24.00   £                  21.00   £                  18.40   
M. Unitary cost for screening positives2  £                  24.38   £                  30.92   £                  21.00   £                  25.76   
N. Total cost for screening negatives [K*I]  £        308,145.60   £          48,595.40   £          10,535.00   £          93,360.99   £        460,636.99  
O. Total cost for screening false reactives [L*H]  £             1,597.03   £                193.09   £                150.90   £                419.67   £            2,360.69  
P. Total cost for screening true positives [M*G]  £             3,535.10   £             4,514.32   £                441.00   £             1,403.92   £            9,894.34  
Q. Staff cost to reach 100% coverage⁶  £        232,564.03   £          74,718.47   £          68,250.72   £          42,910.19   £        418,443.42  
R. Study coordinators (x1 1 WTE)  £          12,500.00   £          12,500.00   £          12,500.00   £          12,500.00   £          50,000.00  
S. Incentives to GPs for testing [£10 for test]     £        134,300.00   £        134,300.00  
T. Promotional material (patient info sheets and 
posters) 
 £                500.00   £                500.00   £                500.00   £                500.00   £            2,000.00  
U. TOTAL COST OF HIV SCREENING PROGRAMME 
SOPHID [N+O+Q+R+S+T] 
 £        558,841.76   £        141,021.28   £          92,377.62   £        285,394.78   £    1,077,635.44  
      
V.Cost for a newly diagnosed HIV patient in 
SOPHIS [U/G] 
 £             3,854.08   £                965.90   £             4,398.93   £             5,236.60   £            2,940.34  
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